Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jubina B Venghateri, Bhavya Jindal & Dulal Panda. (2015) The centrosome: a prospective entrant in cancer therapy. Expert Opinion on Therapeutic Targets 19:7, pages 957-972.
Read now
Read now
Articles from other publishers (25)
Sushmitha Sriramulu, Shivani Thoidingjam, Stephen L. Brown, Farzan Siddiqui, Benjamin Movsas & Shyam Nyati. (2023) Molecular targets that sensitize cancer to radiation killing: From the bench to the bedside. Biomedicine & Pharmacotherapy 158, pages 114126.
Crossref
Crossref
Ayesha Aftab, Ranjha Khan, Uzma Hameed, Tanveer Abbas & Bashir Ahmad. 2022. Breast Cancer: From Bench to Personalized Medicine. Breast Cancer: From Bench to Personalized Medicine
281
336
.
Bernard Barlaam, Chris De Savi, Allan Dishington, Lisa Drew, Andrew D. Ferguson, Douglas Ferguson, Chungang Gu, Sudhir Hande, Lorraine Hassall, Janet Hawkins, Alexander W. Hird, Jane Holmes, Michelle L. Lamb, Andrew S. Lister, Thomas M. McGuire, Jane E. Moore, Nichole O’Connell, Anil Patel, Kurt G. Pike, Ujjal Sarkar, Wenlin Shao, Darren Stead, Jeffrey G. Varnes, Melissa M. Vasbinder, Lei Wang, Liangwei Wu, Lin Xue, Bin Yang & Tieguang Yao. (2021) Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. Journal of Medicinal Chemistry 64:20, pages 15189-15213.
Crossref
Crossref
Lucia Gutierrez-Chamorro, Eudald Felip, Ifeanyi Jude Ezeonwumelu, Mireia Margelí & Ester Ballana. (2021) Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics. Trends in Microbiology 29:9, pages 836-848.
Crossref
Crossref
Nihay Laham-Karam, Gaspar P. Pinto, Antti Poso & Piia Kokkonen. (2020) Transcription and Translation Inhibitors in Cancer Treatment. Frontiers in Chemistry 8.
Crossref
Crossref
Monika Mackiewicz, Ulrike Seitzer, Jabbar S. Ahmed & Norbert Reiling. (2020)
Theileria annulata
surface protein (TaSP) is a target of cyclin‐dependent kinase 1 phosphorylation in Theileria annulata‐infected cells
. Transboundary and Emerging Diseases 67:S1, pages 40-55.
Crossref
Crossref
Mostafa M. Ghorab, Fatma A. Ragab, Helmy I. Heiba, Mohamed S.A. Elsayed & Walid M. Ghorab. (2018) Design, synthesis and molecular modeling study of certain 4-Methylbenzenesulfonamides with CDK2 inhibitory activity as anticancer and radio-sensitizing agents. Bioorganic Chemistry 80, pages 276-287.
Crossref
Crossref
Liandong Jing, Yanbo Tang, Masuo Goto, Kuo-Hsiung Lee & Zhiyan Xiao. (2018)
SAR study on
N
2
,
N
4
-disubstituted pyrimidine-2,4-diamines as effective CDK2/CDK9 inhibitors and antiproliferative agents
. RSC Advances 8:22, pages 11871-11885.
Crossref
Crossref
Koji Ono, Hiroshi Banno, Masanori Okaniwa, Takaharu Hirayama, Naoki Iwamura, Yukiko Hikichi, Saomi Murai, Maki Hasegawa, Yuka Hasegawa, Kazuko Yonemori, Akito Hata, Kazunobu Aoyama & Douglas R. Cary. (2017) Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3′,4′:3,4]benzo[1,2- d ]isothiazole derivatives. Bioorganic & Medicinal Chemistry 25:8, pages 2336-2350.
Crossref
Crossref
Christopher R. CoxonElizabeth AnscombeSuzannah J. Harnor, Mathew P. MartinBenoit CarbainBernard T. GoldingIan R. HardcastleLisa K. HarlowSvitlana KorolchukChristopher J. MathesonDavid R. NewellMartin E. M. NobleMangaleswaran SivaprakasamSusan J. TudhopeDavid M. TurnerLan Z. WangStephen R. WedgeChristopher WongRoger J. GriffinJane A. EndicottCéline Cano. (2017) Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry 60:5, pages 1746-1767.
Crossref
Crossref
Pascale Hazel, Sebastian H. B. Kroll, Alexander Bondke, Marion Barbazanges, Hetal Patel, Matthew J. Fuchter, R Charles Coombes, Simak Ali, Anthony G. M. Barrett & Paul S. Freemont. (2017) Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem 12:5, pages 372-380.
Crossref
Crossref
Stefano Ferrari & Christian Gentili. (2016) Maintaining Genome Stability in Defiance of Mitotic DNA Damage. Frontiers in Genetics 7.
Crossref
Crossref
Oriana Tabarrini, Jenny Desantis & Serena Massari. (2016) Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV. Future Medicinal Chemistry 8:4, pages 421-442.
Crossref
Crossref
Mary E. Law, Patrick E. Corsino, Satya Narayan & Brian K. Law. (2015) Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Molecular Pharmacology 88:5, pages 846-852.
Crossref
Crossref
Concepción Sánchez-Martínez, Lawrence M. Gelbert, María José Lallena & Alfonso de Dios. (2015) Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorganic & Medicinal Chemistry Letters 25:17, pages 3420-3435.
Crossref
Crossref
Chaoxin Hu, Tikva Dadon, Venugopal Chenna, Shinichi Yabuuchi, Rajat Bannerji, Robert Booher, Peter Strack, Nilofer Azad, Barry D. Nelkin & Anirban Maitra. (2015) Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Molecular Cancer Therapeutics 14:7, pages 1532-1539.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
391
491
.
C Delehouzé, K Godl, N Loaëc, C Bruyère, N Desban, N Oumata, H Galons, T I Roumeliotis, E G Giannopoulou, J Grenet, D Twitchell, J Lahti, N Mouchet, M-D Galibert, S D Garbis & L Meijer. (2013) CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene 33:50, pages 5675-5687.
Crossref
Crossref
E X Chen, S Hotte, H Hirte, L L Siu, J Lyons, M Squires, S Lovell, S Turner, L McIntosh & L Seymour. (2014) A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. British Journal of Cancer 111:12, pages 2262-2267.
Crossref
Crossref
Cécile Voisset, Néstor García-Rodríguez, April Birkmire, Marc Blondel & Ralf Erik Wellinger. (2014) Using yeast to model calcium-related diseases: Example of the Hailey–Hailey disease. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1843:10, pages 2315-2321.
Crossref
Crossref
Gaëlle Mariaule & Philippe Belmont. (2014) Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey. Molecules 19:9, pages 14366-14382.
Crossref
Crossref
Aurélien Putey, Guy Fournet, Olivier Lozach, Lionel Perrin, Laurent Meijer & Benoît Joseph. (2014) Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors. European Journal of Medicinal Chemistry 83, pages 617-629.
Crossref
Crossref
Oussama Dehbi, Abdellatif Tikad, Stéphane Bourg, Pascal Bonnet, Olivier Lozach, Laurent Meijer, Mina Aadil, Mohammed Akssira, Gérald Guillaumet & Sylvain Routier. (2014) Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors. European Journal of Medicinal Chemistry 80, pages 352-363.
Crossref
Crossref
Benoit CarbainDavid J. PatersonElizabeth AnscombeAllyson J. CampbellCeline CanoAude EchalierJane A. EndicottBernard T. GoldingKaren HaggertyIan R. HardcastlePhilip J. JewsburyDavid R. NewellMartin E. M. NobleCeline RocheLan Z. WangRoger J. Griffin. (2013)
8-Substituted
O
6
-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode
. Journal of Medicinal Chemistry 57:1, pages 56-70.
Crossref
Crossref
Céline Bruyère & Laurent Meijer. (2013) Targeting cyclin-dependent kinases in anti-neoplastic therapy. Current Opinion in Cell Biology 25:6, pages 772-779.
Crossref
Crossref